Similar articles

• Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation.

  Taketomi A, Sanefuji K, Soejima Y, Yoshizumi T, Uhciyama H, Ikegami T, Harada N, Yamashita Y, Sugimachi K, Kayashima H, Iguchi T, Maehara Y. Taketomi A, et al. Transplantation. 2009 Feb 27;87(4):531-7. doi: 10.1097/TP.0b013e3181943bee. Transplantation. 2009. PMID: 19307789
• Tools for monitoring patients with hepatocellular carcinoma on the waiting list and after liver transplantation.

  Kneteman N, Livraghi T, Madoff D, de Santibañez E, Kew M. Kneteman N, et al. Liver Transpl. 2011 Oct;17 Suppl 2:S117-27. doi: 10.1002/lt.22334. Liver Transpl. 2011. PMID: 21584926 Review. No abstract available.
• Should the liver transplant criteria for hepatocellular carcinoma be different for deceased donation and living donation?

  Grant D, Fisher RA, Abecassis M, McCaughan G, Wright L, Fan ST. Grant D, et al. Liver Transpl. 2011 Oct;17 Suppl 2:S133-8. doi: 10.1002/lt.22348. Liver Transpl. 2011. PMID: 21634006 Review. No abstract available.
• Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation.

  Ito T, Takada Y, Ueda M, Haga H, Maetani Y, Oike F, Ogawa K, Sakamoto S, Ogura Y, Egawa H, Tanaka K, Uemoto S. Ito T, et al. Liver Transpl. 2007 Dec;13(12):1637-44. doi: 10.1002/lt.21281. Liver Transpl. 2007. PMID: 18044766
• Which matters most: number of tumors, size of the largest tumor, or total tumor volume?

  Germani G, Gurusamy K, Garcovich M, Toso C, Fede G, Hemming A, Suh KS, Weber A, Burroughs AK. Germani G, et al. Liver Transpl. 2011 Oct;17 Suppl 2:S58-66. doi: 10.1002/lt.22336. Liver Transpl. 2011. PMID: 21584928 Review. No abstract available.